{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Durable Response Rate (DRR) defined as the proportion of patients who achieved a confirmed complete or partial response (CR or PR) and maintained that response for at least 6 months.","groups":[{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV\n\nDocetaxel: Given IV\n\nEtoposide: Given IV\n\nPembrolizumab: Given IV","id":"OG000","title":"Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer"},{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2: Small Cell or Neuroendocrine Prostate Cancer"}],"paramType":"NUMBER","populationDescription":"one patient withdrew Cohort 2","reportingStatus":"POSTED","timeFrame":"At 6 months","title":"Durable Response Rate (DRR) (Cohorts 1 and 2)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}